Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Elacestrant in Severe Hepatic Impairment
NCT06126575Phase 1Completed
- Sponsor
- Stemline Therapeutics
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of elacestrant in breast cancer, sponsored by Stemline Therapeutics. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to the last measurable concentration and 1 more. Started Mar 2023; status: completed.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06126575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126575.